New drug aims to stop immune system from attacking transplanted livers

NCT ID NCT06455280

Recruiting now Disease control Sponsor: Elizabeth C. Verna Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests whether siplizumab, given at the time of liver transplant, can safely prevent the immune system from attacking the new liver. Up to 8 adults with autoimmune hepatitis or primary sclerosing cholangitis will receive two doses. The main goal is to check for serious infections in the first month, while also watching for rejection or disease return over 12 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CIRRHOSIS, LIVER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune hepatitis Cholangitis, Sclerosing chronic liver failure cirrhosis of liver End Stage Liver Disease primary sclerosing cholangitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE HEPATITIS AUTOIMMUNE LIVER DISEASE CIRRHOSIS, LIVER END STAGE LIVER DISEASE LIVER TRANSPLANT DISORDER PRIMARY SCLEROSING CHOLANGITIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Columbia University Irving Medical Center/NewYork-Presbyterian Hospital
RECRUITING

New York, New York, 10032, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••